ALTSTAETTEN, Switzerland and EAST HARTFORD, Conn. , January 25, 2024 /PRNewswire/ — icotec ag, a leader in innovative spinal tumor implants, is excited to announce a major milestone in its growth trajectory by establishing a strategic partnership with MVM Partners, a global venture capital firm specializing in healthcare. The company commercializes the revolutionary BlackArmor® carbon/PEEK products, which have the potential to provide significant clinical benefits over traditional metal implants in the spinal oncology setting, fully realizing the potential of treatment options available to patients throughout the world. throughout their journey.
Since receiving FDA approval in 2019, many designated U.S. cancer centers have adopted icotec’s BlackArmor® products. This investment will enable icotec to maintain its remarkable growth and strengthen its research and development capabilities to expand its portfolio into the underserved indications of spinal infections and osteoporosis.
“We are delighted to collaborate with MVM, whose deep understanding of the medical landscape aligns perfectly with our vision for the future,” said Roger Stadler, CEO of icotec ag group. “This partnership marks a turning point for icotec as it allows us to continue our mission of improving patient outcomes by providing a compelling alternative to metal implant technology that has been around for over 100 years. » 
MVM has a strong reputation for supporting and partnering with innovative healthcare companies and recognizes the potential of icotec’s technology to transform patient care. This partnership demonstrates confidence in icotec’s leadership, products and overall trajectory.
“We are delighted to support icotec in its goal to revolutionize the spinal implant industry,” said Thomas Casdagli, Partner at MVM. “Icotec’s BlackArmor® carbon/PEEK implants represent a significant advancement in the treatment of complex spinal conditions. For the first time, clinicians have the ability to accurately view and treat patients after surgery, without the artifacts and limitations of traditional metal implants. We see this as a major advancement in patient care. We look forward to working closely with the icotec team to continue our success and growth. »
WISTAMA Finanz- und Beteiligungs AG, the family office of the Stadler family that founded icotec, remains fully invested as majority shareholder and committed to the long-term development of icotec.
For any inquiries, please contact:
Remo Keller, Group Chief Financial Officer, remo.keller@icotec-medical.com , +41 71 757 00 96
About icotec ag
icotec positions itself as a leader in the treatment of spinal tumors thanks to a new generation of cutting-edge implants. icotec’s BlackArmor® carbon/PEEK implants are the result of combining cutting-edge technologies and industry expertise, providing innovative and reliable solutions for spine surgeons and their patients. The company is committed to advancing the field of spinal implantation. Building on clinical successes and a continued commitment to innovation, icotec is strongly positioned to influence the future of spinal surgery. Its comprehensive product portfolio has received FDA approval and is supported by many influential thought leaders as well as cancer treatment centers around the world. For more information, visit www.icotec-medical.com.
About MVM Partners
Since 1997, MVM has invested in high-growth healthcare companies. With teams based in Boston and London, MVM takes a global investment perspective that spans medical technology, pharmaceuticals, diagnostics, contract research and manufacturing, digital health, and other healthcare sectors health. For more information, visit www.mvm.com .
